Announcements and Circulars-宜明昂科英文

Investor Relations

Information Disclosure

Announcements and Circulars Analyst Report Financial Reports Listing Documents

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 June 2025

VOLUNTARY ANNOUNCEMENT - CLEARANCE OF IND APPLICATION FOR IMM2510/AXN-2510 BY THE U.S. FDA

Terms of Reference of the Nomination Committee

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE

VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR THE CLINICAL TRIAL OF IMC-003/IMM72

DISCLOSEABLE TRANSACTIONS - REDEMPTION AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS

DISCLOSEABLE TRANSACTIONS - REDEMPTION AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS

VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF CHIEF MEDICAL OFFICER

(Revised) Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2025

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2025

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

I. POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 28, 2025; II. APPOINTMENT OF DIRECTOR

SUPPLEMENTAL ANNOUNCEMENT - DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS

VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIALS OF IMM2510/AXN-2510 IN COMBINATION WITH CHEMOTHERAPY IN FIRST-LINE NSCLC

Next Day Disclosure Return

INSIDE INFORMATION - COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2025

VOLUNTARY ANNOUNCEMENT - FURTHER PAYMENT RECEIVED UNDER THE LICENSE AND COLLABORATION AGREEMENT WITH AXION BIO FOR IMM2510 (PALVERAFUSP) AND IMM27M (TAZLESTOBART)

VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF CHIEF BUSINESS OFFICER

总计 147 123 4 5 6 7 8